These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8272810)

  • 1. [Therapy of resistant gram-positive infection: value of glycopeptide antibiotics vancomycin and teicoplanin].
    Waldvogel F
    Schweiz Med Wochenschr; 1993 Dec; 123(50):2353-6. PubMed ID: 8272810
    [No Abstract]   [Full Text] [Related]  

  • 2. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].
    Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):293-300. PubMed ID: 9265387
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging glycopeptide resistance in gram-positive organisms.
    von Gottberg A; Ferraz V; Dusé AG
    S Afr Med J; 2000 Nov; 90(11):1108-9. PubMed ID: 11196027
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A; Arthur M; Depardieu F; Chau F; Pouzet C; Courvalin P; Fantin B
    J Infect Dis; 2004 Jan; 189(1):90-7. PubMed ID: 14702158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First case of infection due to vancomycin resistant Enterococcus faecalis in New Caledonia].
    Garin B; Barny S; Lechevallier S; Agathe-Nerine J
    Med Mal Infect; 2006 May; 36(5):297-8. PubMed ID: 16631333
    [No Abstract]   [Full Text] [Related]  

  • 10. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What do I need to know about glycopeptide antibiotics?
    Li S; Starkey ES
    Arch Dis Child Educ Pract Ed; 2016 Dec; 101(6):323-326. PubMed ID: 27389546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glycopeptides (vancomycin, teicoplanin)--their place in the antibacterial therapy of patients in a high-risk group].
    Beloborodova NV
    Anesteziol Reanimatol; 1998; (4):23-7. PubMed ID: 9770813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Teicoplanin. New treatment potentials for gram-positive infections in the hospital].
    Iakovlev SV
    Antibiot Khimioter; 1999; 44(2):3-7. PubMed ID: 10202550
    [No Abstract]   [Full Text] [Related]  

  • 16. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

  • 17. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.